Company intelligence / Profile preview

MimiVax

Buffalo, New York, United Statesmimivax.com ↗

Ownership: Private
Employees: ~30
Development stage: Phase 2

Overview

MimiVax’s lead candidate, SurVaxM, has shown encouraging results in clinical trials for newly diagnosed glioblastoma. In a multi-center Phase IIa trial, median progression-free survival was reported at 11.4 months and median overall survival at nearly 26 months from first immunization—outcomes that compare favorably to historical controls. The ongoing fully enrolled Phase IIb SURVIVE trial continues after a positive interim futility analysis. SurVaxM has also received FDA Fast Track Designation and expanded Orphan Drug Designation for malignant gliomas.

Therapeutic areas: Oncology
Modalities: Peptide vaccines (immunotherapeutic vaccines)Targeted therapies
Industry: Biotech

Drug pipeline

5 assets

SurVaxM

4 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with Roswell Park Comprehensive Cancer Centerpartnership-sponsored trials with pharmaceutical companies are sought but not specifically named

Beyond the preview

Go deeper on MimiVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MimiVax.

Explore the full profile